MCID: VLV011
MIFTS: 51

Vulvovaginal Candidiasis

Categories: Infectious diseases, Reproductive diseases

Aliases & Classifications for Vulvovaginal Candidiasis

MalaCards integrated aliases for Vulvovaginal Candidiasis:

Name: Vulvovaginal Candidiasis 12 3 15
Candidiasis, Vulvovaginal 44 73
Candidiasis of Vulva and Vagina 12
Candidiasis Vulvovaginal 55
Candidal Vulvovaginitis 12
Monilial Vulvovaginitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2272
ICD10 33 B37.3
ICD9CM 35 112.1
MeSH 44 D002181
NCIt 50 C2914
UMLS 73 C0700345

Summaries for Vulvovaginal Candidiasis

CDC : 3 Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on skin without causing any problems. Sometimes Candida can multiply and cause an infection if the environment inside the vagina changes in a way that encourages its growth. Candidiasis in the vagina is commonly called a “vaginal yeast infection.” Other names for this infection are “vaginal candidiasis,” “vulvovaginal candidiasis,” or “candidal vaginitis.”

MalaCards based summary : Vulvovaginal Candidiasis, also known as candidiasis, vulvovaginal, is related to trichomoniasis and bacterial vaginosis. An important gene associated with Vulvovaginal Candidiasis is MBL2 (Mannose Binding Lectin 2), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Miconazole and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and colon, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A candidiasis that involves fungal infection of the vaginal mucous membranes in women caused by Candida albicans. The symptoms include intense vulval pruritus, burning, erythema and dyspareunia associated with a creamy white, curd-like discharge.

Related Diseases for Vulvovaginal Candidiasis

Diseases related to Vulvovaginal Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 162)
# Related Disease Score Top Affiliating Genes
1 trichomoniasis 31.0 CD79A IL2
2 bacterial vaginosis 31.0 DEFB4A MBL2
3 candidiasis 30.8 CD79A CLEC7A DEFB4A IFNG
4 vulvar vestibulitis syndrome 30.7 MBL2 NLRP3
5 vulvovaginitis 11.2
6 immunoglobulin g deficiency 10.8 CD79A MBL2
7 vaginitis 10.7
8 coccidioidomycosis 10.7 CLEC7A MBL2
9 immunoglobulin alpha deficiency 10.7 CD79A MBL2
10 urethritis 10.7 CD79A DEFB4A
11 cutaneous mycosis 10.6 CLEC7A DEFB4A
12 pneumocystosis 10.6 CD79A CLEC7A
13 corneal abscess 10.6 DEFB1 DEFB4A
14 osteonecrosis of the jaw 10.6 DEFB1 DEFB4A
15 indeterminate leprosy 10.5 CD79A DEFB1
16 farmer's lung 10.5 CD79A IL2
17 mycobacterium abscessus 10.5 CLEC7A NLRP3
18 oral candidiasis 10.5 DEFB1 DEFB4A
19 immunoglobulin a deficiency 1 10.4 CD79A IL4
20 congenital hypogammaglobulinemia 10.4 CD79A IL4
21 parasitic ichthyosporea infectious disease 10.4 CD79A IL4
22 rhinosporidiosis 10.4 CD79A IL4
23 immunodeficiency with hyper-igm, type 1 10.4 CD79A IL4
24 commensal bacterial infectious disease 10.4 CD79A IL2
25 gastrointestinal allergy 10.3 CD79A IL4
26 chromoblastomycosis 10.3 CLEC7A IL4
27 primary amebic meningoencephalitis 10.3 CD79A IL4
28 allergic bronchopulmonary aspergillosis 10.3 IL4 MBL2
29 rheumatic fever 10.3 IL2 MBL2
30 aging 10.3
31 candida glabrata 10.3
32 milk allergy 10.2 CD79A IL4
33 periodontal disease 10.2 CD79A DEFB1 DEFB4A
34 granulomatous hepatitis 10.2 CD79A IL4
35 wells syndrome 10.2 IL2 NLRP3
36 neuroschistosomiasis 10.2 CD79A IFNG
37 virus associated hemophagocytic syndrome 10.2 IL2 IL4
38 sporotrichosis 10.2 CD79A IFNG
39 jak3-deficient severe combined immunodeficiency 10.1 IL2 IL4
40 cervicitis 10.1 CD79A DEFB4A IL2
41 angiostrongyliasis 10.1 IL2 IL4
42 ocular cicatricial pemphigoid 10.1 CD79A IL4
43 strongyloidiasis 10.1 CD79A IFNG
44 chronic graft versus host disease 10.1 CD79A IFNG
45 diabetes mellitus 10.1
46 rheumatic heart disease 10.1 IL4 MBL2
47 cryptococcal meningitis 10.1 IFNG MBL2
48 aphthous stomatitis 10.0 IL4 NLRP3
49 exanthem 10.0 CD79A IL2 NLRP3
50 keratoconjunctivitis sicca 10.0 CD79A IL4

Comorbidity relations with Vulvovaginal Candidiasis via Phenotypic Disease Network (PDN): (show all 12)


Acute Cystitis Anxiety
Bronchitis Decubitus Ulcer
Deficiency Anemia Esophagitis
Heart Disease Hypertension, Essential
Hypothyroidism Oral Candidiasis
Osteoporosis Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Vulvovaginal Candidiasis:



Diseases related to Vulvovaginal Candidiasis

Symptoms & Phenotypes for Vulvovaginal Candidiasis

MGI Mouse Phenotypes related to Vulvovaginal Candidiasis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.86 CD101 CD79A CLEC7A IFNG IL2 IL4
2 immune system MP:0005387 9.76 NLRP3 CD101 CD79A CLEC7A IFNG IL2
3 digestive/alimentary MP:0005381 9.72 NLRP3 CLEC7A IFNG IL2 IL4
4 liver/biliary system MP:0005370 9.35 NLRP3 CD79A IFNG IL2 IL4
5 renal/urinary system MP:0005367 9.02 NLRP3 CD79A IFNG IL4 MBL2

Drugs & Therapeutics for Vulvovaginal Candidiasis

Drugs for Vulvovaginal Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
2
Fluconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 86386-73-4 3365
3
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Early Phase 1,Not Applicable 18323-44-9 29029
4
Clotrimazole Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23593-75-1 2812
5
Dequalinium Approved, Investigational Phase 4 6707-58-0
6
Terconazole Approved Phase 4,Not Applicable,Early Phase 1 67915-31-5 441383
7
Metronidazole Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 443-48-1 4173
8
Ephedrine Approved Phase 4 299-42-3 9294
9
Pseudoephedrine Approved Phase 4 90-82-4 7028
10 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Clindamycin palmitate Phase 4,Phase 3,Early Phase 1,Not Applicable
19 Clindamycin phosphate Phase 4,Phase 3,Early Phase 1,Not Applicable
20 Anti-Infective Agents, Local Phase 4,Phase 3
21 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
22 Immune Sera Phase 4
23 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
24 Antibiotics, Antitubercular Phase 4,Phase 3,Not Applicable
25 Antitubercular Agents Phase 4,Phase 3
26 Tetrahydrozoline Phase 4,Phase 3
27 Autonomic Agents Phase 4
28 Nasal Decongestants Phase 4
29 Ophthalmic Solutions Phase 4
30 Peripheral Nervous System Agents Phase 4
31 Pharmaceutical Solutions Phase 4
32 Respiratory System Agents Phase 4
33 Vasoconstrictor Agents Phase 4
34
Amphotericin B Approved, Investigational Phase 3,Phase 2 1397-89-3 14956 5280965
35
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576 3823
36
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
37
Azithromycin Approved Phase 3 83905-01-5 55185 447043
38
Rifabutin Approved, Investigational Phase 3 72559-06-9 6323490
39
Tinidazole Approved, Investigational Phase 3 19387-91-8 5479
40
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
41
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
42
leucovorin Approved, Nutraceutical Phase 3 58-05-9 143 6006
43 Antiparasitic Agents Phase 3,Phase 2,Early Phase 1,Not Applicable
44 Antiprotozoal Agents Phase 3,Phase 2,Early Phase 1,Not Applicable
45 Liposomal amphotericin B Phase 3,Phase 2
46 Alkylating Agents Phase 3
47 Antimetabolites Phase 3
48 Antimetabolites, Antineoplastic Phase 3
49 Antirheumatic Agents Phase 3
50 Dermatologic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 60)
# Name Status NCT ID Phase Drugs
1 Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
2 Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis Completed NCT02248506 Phase 4
3 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
4 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
5 Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina Completed NCT00194324 Phase 4 Miconazole nitrate
6 Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis Completed NCT00556179 Phase 4 Lactoserum (Dermacyd Femina®)
7 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Recruiting NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
8 The Study Of Fluconazole For Vulvovaginal Candidiasis Completed NCT01806623 Phase 3 Fluconazole
9 Diabetes Mellitus and Vulvovaginal Candidiasis Completed NCT00353561 Phase 3 Boric;Fluconazole
10 Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis Completed NCT02251093 Phase 3 Lcr Regenerans;Placebo
11 A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) Completed NCT01293643 Phase 3 100 mg clindamycin /800 mg ketoconazole vaginal ovule;100 mg tetracycline hydrochloride /50 mg amphotericin B cream
12 Comparative Efficacy of Ovule vs Tablet Completed NCT00755053 Phase 3 Clotrimazole, vaginal ovule;Clotrimazole, vaginal tablet
13 A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients Completed NCT00002122 Phase 3 Azithromycin;Rifabutin;Fluconazole
14 Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments Completed NCT00313131 Phase 3 tinidazole+fluconazole vs metronidazole+clotrimazole
15 A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants Completed NCT01941940 Phase 3 Tocilizumab;DMARDs
16 ProF-001_Phase IIa Recruiting NCT03115073 Phase 2, Phase 3 Candiplus;Clotrimazole
17 Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Cream. Recruiting NCT03005353 Phase 2, Phase 3 Cumin seed extract;clotrimazole
18 Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis Not yet recruiting NCT02907307 Phase 3 Clotrimazole vaginal tablet 100mg
19 Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis Not yet recruiting NCT03473418 Phase 3 Ketoconazole;Terconazole
20 A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Not yet recruiting NCT03562156 Phase 3 VT-1161;Placebo
21 A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Not yet recruiting NCT03561701 Phase 3 VT-1161;Placebo
22 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Completed NCT02267382 Phase 2 VT-1161;Placebo
23 Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis Completed NCT01926028 Phase 1, Phase 2
24 MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis Completed NCT01497223 Phase 2 MGCD290
25 Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Completed NCT02679456 Phase 2 SCY-078;Fluconazole
26 An Active-Controlled, Dose-Finding Study of SCY-078 vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Completed NCT03253094 Phase 2 Fluconazole;SCY-078
27 Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment Completed NCT01144286 Phase 2 arasertaconazole nitrate;placebo
28 A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) Completed NCT01891331 Phase 2 VT-1161;Fluconazole
29 Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Completed NCT02971007 Phase 2 Oral Encochleated Amphotericin B (CAMB);Fluconazole
30 Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women Completed NCT01230814 Phase 2 Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate);Placebo
31 RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections Completed NCT02733432 Phase 2 CD101 Vaginal Gel (3%);CD101 External gel (1%);CD101 Vaginal Ointment (6%);CD101 External ointment (1%);Fluconazole
32 TOL-463 Phase 2 Study for Vaginitis Completed NCT02866227 Phase 2 TOL-463;TOL-463
33 Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis Completed NCT00635622 Phase 2 LACTIN-V;Placebo control substance
34 Patients With Vulvovaginal Candidiasis Not yet recruiting NCT03024502 Phase 1, Phase 2 EPP-AF Gel 1%;EPP-AF Gel 2%;Clotrimazole
35 Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis Not yet recruiting NCT03167957 Phase 2 Oral Encochleated Amphotericin B (CAMB);Oral Encochleated Amphotericin B (CAMB)
36 Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis Unknown status NCT00479947 Phase 1 Probiotics (Natural product);Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)
37 Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection Completed NCT01067131 Phase 1
38 Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463 Completed NCT01812889 Phase 1 TOL-463 Vaginal ovule;TOL-463 Vaginal gel
39 Will Vaginal Colonization of Lactobacillus Increase Cure Rate After Treatment of Bacterial Vaginosis and Chronic Vulvovaginal Candida Unknown status NCT02295579
40 Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method Unknown status NCT02558179
41 Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis Completed NCT00803738 Not Applicable Terconazole Vaginal Suppository;Terazol Vaginal Suppository
42 Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) Completed NCT00895453 Not Applicable itraconazole;lactobacillus gasseri;classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)
43 A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations Completed NCT01039584 Not Applicable Butoconazole Nitrate Vaginal Cream;Placebo;Gynazole 1 vaginal cream
44 Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization Completed NCT02888197
45 Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis Completed NCT02203942
46 Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women Completed NCT02150655 Early Phase 1
47 Observational Program Neo-Penotran® Forte Completed NCT01335373 Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)
48 A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients Completed NCT00002438 Not Applicable Itraconazole
49 Management of Vaginal Complaints: A Pilot Study Within a Practice-Based Research Network Completed NCT00503542 Early Phase 1 Terazol or oral fluconazole for candidal vaginitis;Metronidazole or Clindamycin for Bacterial Vaginosis;Flagyl for definitively diagnosed vaginal trichomoniasis
50 Epidemiological Study in Subjects With Vulvovaginal Candidiases Recruiting NCT03064789

Search NIH Clinical Center for Vulvovaginal Candidiasis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: candidiasis, vulvovaginal

Genetic Tests for Vulvovaginal Candidiasis

Anatomical Context for Vulvovaginal Candidiasis

MalaCards organs/tissues related to Vulvovaginal Candidiasis:

41
Skin, Testes, Colon, Neutrophil, B Cells

Publications for Vulvovaginal Candidiasis

Articles related to Vulvovaginal Candidiasis:

(show top 50) (show all 420)
# Title Authors Year
1
Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy. ( 29975334 )
2018
2
New evidence on oral L. plantarum P17630 product in women with history of recurrent vulvovaginal candidiasis (RVVC): a randomized double-blind placebo-controlled study. ( 29364495 )
2018
3
Risk Factors of Vulvovaginal Candidiasis among Women of Reproductive Age in Xi'an: A Cross-Sectional Study. ( 29977925 )
2018
4
Risk of major congenital malformations following first-trimester exposure to vaginal azoles used for treating vulvovaginal candidiasis: a population-based retrospective cohort study. ( 29790255 )
2018
5
A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate theA efficacy and safety of orally administeredA VT-1161 inA the treatment of recurrentA vulvovaginal candidiasis. ( 29534874 )
2018
6
Pulsatilla decoction inhibits Candida albicans proliferation and adhesion in a mouse model of vulvovaginal candidiasis via the Dectin-1 signaling pathway. ( 29775695 )
2018
7
Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis. ( 29963049 )
2018
8
Surface-modified mucoadhesive microgels as a controlled release system for miconazole nitrate to improve localized treatment of vulvovaginal candidiasis. ( 28986195 )
2018
9
Novel Mechanism behind the Immunopathogenesis of Vulvovaginal Candidiasis: "Neutrophil Anergy". ( 29203543 )
2018
10
Antifungal susceptibilities, in vitro production of virulence factors and activities of ceragenins against Candida spp. isolated from vulvovaginal candidiasis. ( 29846682 )
2018
11
The effect of a vaginal suppository formulation of dill (Anethum graveolens) in comparison to clotrimazole vaginal tablet on the treatment of vulvovaginal candidiasis. ( 29553834 )
2018
12
Nanolipid Gel of an Antimycotic Drug for Treating Vulvovaginal Candidiasis-Development and Evaluation. ( 29340981 )
2018
13
Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. ( 29902998 )
2018
14
Thymol, eugenol and lactobacilli in a medical device for the treatment of bacterial vaginosis and vulvovaginal candidiasis. ( 29874389 )
2018
15
Amphotericin B-Loaded Plga Nanofibers: an Alternative Therapy Scheme for Local Treatment of Vulvovaginal Candidiasis. ( 29940181 )
2018
16
Antimicrobial photodynamic therapy as a new approach for the treatment of vulvovaginal candidiasis: preliminary results. ( 29931589 )
2018
17
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. ( 29932786 )
2018
18
RISK FACTORS OF VULVOVAGINAL CANDIDIASIS IN DERMATO-VENEREOLOGY OUTPATIENTS CLINIC OF SOETOMO GENERAL HOSPITAL, SURABAYA, INDONESIA. ( 29619437 )
2018
19
Longitudinal trajectory of vulvovaginal candidiasis, trichomoniasis, and bacterial vaginosis during pregnancy as well as the impact on pregnancy outcomes: a preliminary study. ( 29685081 )
2018
20
A Therapeutic Vaccine for Recurrent Vulvovaginal Candidiasis. ( 29697770 )
2018
21
A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. ( 29697768 )
2018
22
Computer-aided diagnosis software for vulvovaginal candidiasis detection from Pap smear images. ( 28987021 )
2018
23
Development, characterization, and in vitro-in vivo evaluation of polymeric nanoparticles containing miconazole and farnesol for treatment of vulvovaginal candidiasis. ( 29361177 )
2018
24
Mannose-Binding Lectin Gene Polymorphism and Its Association with Susceptibility to Recurrent Vulvovaginal Candidiasis. ( 29850562 )
2018
25
Formulation, stability study, and pre-clinical evaluation of a vaginal cream containing curcumin in a rat model of vulvovaginal candidiasis. ( 29517833 )
2018
26
Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen? ( 28868834 )
2017
27
Recurrent vulvovaginal candidiasis: A review of guideline recommendations. ( 28299777 )
2017
28
Comparison of two long-term gestagen regimens in the management of recurrent vulvovaginal candidiasis: A pilot study. ( 28066940 )
2017
29
Automatic diagnosis of vulvovaginal candidiasis from Pap smear images. ( 28419509 )
2017
30
Effectiveness of Ageratina pichinchensis Extract in Patients with Vulvovaginal Candidiasis. A Randomized, Double-Blind, and Controlled Pilot Study. ( 28299831 )
2017
31
Emergence of Candida glabrata in vulvovaginal candidiasis should be attributed to selective pressure or virulence ability? ( 28730269 )
2017
32
Prevalence of Candida albicans, Candida dubliniensis and Candida africana in pregnant women suffering from vulvovaginal candidiasis in Argentina. ( 28385421 )
2017
33
Comparison of vaginal ointment of honey and clotrimazole for treatment of vulvovaginal candidiasis: A random clinical trial. ( 28760590 )
2017
34
Is MBL serum concentration a reliable predictor for recurrent vulvovaginal candidiasis? ( 29110332 )
2017
35
Biofilms Formed by Isolates from Recurrent Vulvovaginal Candidiasis Patients Are Heterogeneous and Insensitive to Fluconazole. ( 28696240 )
2017
36
Vulvovaginal candidiasis: Etiology, symptomatology and risk factors. ( 28314677 )
2017
37
Efficacy of Histatin5 in a murine model of vulvovaginal candidiasis caused by Candida albicans. ( 28645176 )
2017
38
Recurrent vulvovaginal candidiasis. ( 28927765 )
2017
39
Recurrent vulvovaginal candidiasis: A review of guidelines and recommendations. ( 28967688 )
2017
40
Contribution of TLR2 pathway in the pathogenesis of vulvovaginal candidiasis. ( 28911197 )
2017
41
Clonal spread and azole-resistant mechanisms of non-susceptible Candida albicans isolates from vulvovaginal candidiasis patients in three Shanghai maternity hospitals. ( 29136186 )
2017
42
Molecular Identification and Antifungal Susceptibility Pattern of Non-albicans Candida Species Isolated from Vulvovaginal Candidiasis ( 28688376 )
2017
43
Probiotics for vulvovaginal candidiasis in non-pregnant women. ( 29168557 )
2017
44
Vaginal Candida spp. genomes from women with vulvovaginal candidiasis. ( 28582496 )
2017
45
Characterization of virulence factors of vaginal and anal isolates of Candida albicans sequentially obtained from patients with vulvovaginal candidiasis in north-east Brazil. ( 28844452 )
2017
46
Prevalence of vulvovaginal candidiasis in pregnancy at three health centers in Burkina Faso. ( 28939305 )
2017
47
Candidiasis, Vaginal (Vulvovaginal Candidiasis) ( 29083806 )
2017
48
Fungal Profile of Vulvovaginal Candidiasis in a Tertiary Care Hospital. ( 28511380 )
2017
49
Prevalence of Candida africana and Candida dubliniensis, in vulvovaginal candidiasis: First Turkish Candida africana isolates from vulvovaginal candidiasis. ( 28641919 )
2017
50
Elevated nitric oxide in recurrent vulvovaginal candidiasis - association to clinical findings. ( 28052314 )
2017

Variations for Vulvovaginal Candidiasis

Expression for Vulvovaginal Candidiasis

Search GEO for disease gene expression data for Vulvovaginal Candidiasis.

Pathways for Vulvovaginal Candidiasis

Pathways related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.92 CD101 CD79A CLEC7A DEFB1 DEFB4A IFNG
2
Show member pathways
12.76 IFNG IL2 MBL2 NLRP3
3
Show member pathways
12.54 CD79A IFNG IL2 IL4
4
Show member pathways
12.51 IFNG IL2 IL4 NLRP3
5 12.29 CD79A IFNG IL2 IL4
6
Show member pathways
12.21 IFNG IL2 IL4
7
Show member pathways
12.2 IFNG IL2 IL4
8
Show member pathways
12.1 IFNG IL2 IL4
9
Show member pathways
12.09 DEFB4A IFNG IL4
10
Show member pathways
11.96 CLEC7A IL2 NLRP3
11
Show member pathways
11.93 DEFB4A IFNG IL4
12 11.77 IFNG IL2 IL4
13
Show member pathways
11.72 IFNG IL2 IL4
14 11.55 IFNG IL2 IL4
15 11.52 CD79A IFNG IL2 IL4
16
Show member pathways
11.49 IFNG IL2 IL4
17 11.24 IFNG IL2 IL4
18 11.16 CD101 IFNG IL2 IL4
19 11.1 IFNG IL4
20 11.06 IFNG IL2 IL4
21 11.02 IFNG IL2
22 10.97 IFNG NLRP3
23 10.97 IFNG IL2 IL4
24 10.85 IFNG IL2 IL4

GO Terms for Vulvovaginal Candidiasis

Cellular components related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 DEFB1 DEFB4A IFNG IL2 IL4 MBL2
2 extracellular region GO:0005576 9.17 DEFB1 DEFB4A IFNG IL2 IL4 MBL2

Biological processes related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.76 CLEC7A DEFB1 MBL2 NLRP3
2 adaptive immune response GO:0002250 9.71 CD79A IFNG IL2
3 defense response to bacterium GO:0042742 9.67 DEFB1 DEFB4A MBL2
4 defense response GO:0006952 9.58 DEFB1 DEFB4A NLRP3
5 immune system process GO:0002376 9.55 CD79A CLEC7A IL2 MBL2 NLRP3
6 positive regulation of B cell proliferation GO:0030890 9.52 IL2 IL4
7 response to bacterium GO:0009617 9.51 DEFB1 NLRP3
8 B cell activation GO:0042113 9.48 CD79A IL4
9 positive regulation of T cell differentiation GO:0045582 9.43 IL2 IL4
10 regulation of regulatory T cell differentiation GO:0045589 9.37 IFNG IL2
11 immune response GO:0006955 9.35 DEFB1 DEFB4A IFNG IL2 IL4
12 positive regulation of isotype switching to IgG isotypes GO:0048304 9.32 IL2 IL4
13 positive regulation of interleukin-13 production GO:0032736 9.26 IL4 NLRP3
14 defense response to Gram-positive bacterium GO:0050830 8.92 DEFB1 DEFB4A MBL2 NLRP3

Molecular functions related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.33 IFNG IL2 IL4
2 carbohydrate binding GO:0030246 9.13 CLEC7A IL2 MBL2
3 CCR6 chemokine receptor binding GO:0031731 8.62 DEFB1 DEFB4A

Sources for Vulvovaginal Candidiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....